An interventional study of Active FlowOx™ and Sham FlowOx™ (Placebo) in Peripheral Vascular Disease, Intermittent Claudication and Walking, Difficulty, sponsored by Otivio AS. Terminated at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-25.
Sponsored by Otivio AS · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Peripheral Vascular Diseases with a site in Germany — 6 open to participants now, 8 under way, 1 of them phase 3. Peripheral Vascular Diseases · Germany.
Among the 64 studies in Peripheral Vascular Diseases with a site in Germany, this one is the 48th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2019, is one of 25 with no phase, and was the 48th registered.
443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.
Browse Peripheral Vascular Diseases studies →6 of the 64 studies in Peripheral Vascular Diseases with a site in Germany are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in Germany
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18–85
University of Leipzig · Sites in Germany, Austria
Ages 18+
Ulrich Rother · Sites in Germany
Ages 18+
Balt Extrusion · Sites in Germany, France, Spain
Ages 2+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 9
First in 2002; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 327 interventional studies indexed under Peripheral Vascular Diseases.
Median enrollment 111 across the 50 interventional studies, 230 across the 14 observational. Of the 44 that completed or were terminated, 12 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 64 have an industry lead sponsor. The 10 most frequent:
Otivio AS is the lead sponsor of 5 studies on the registry; none are open to participants now.
Otivio AS has 1 study filed under Peripheral Vascular Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Peripheral Vascular Diseases with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971772Cardionovum GmbHSIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 64 studies in Peripheral Vascular Diseases with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market. The study will be carried out in a patient population with peripheral artery disease (claudicatio intermittens) to confirm its usefulness and in particular gather information for further improvements of the device related to this patient population. The data collected from the use of the CE-marked FlowOX™ device are change of walking distance, quality of life, and the patient's compliance.
A multi-center, randomized, sham (placebo)-controlled, double-blind trial to assess the efficacy and safety of FlowOx. This is done by comparing the increase in pain free walking distance compared to sham (placebo) device in patients with peripheral arterial disease (PAD) and intermittent claudication.
This study is conducted to assess the efficacy and safety of FlowOx™ compared to a sham FlowOx™ (placebo) device treatment. FlowOx™ can provide intermittent negative pressure (up to - 40 mmHg INP [intermittent negative pressure]) which is known to improve blood flow. The same device will also work as a sham (placebo) device by less negative pressure exerted by the device (in the range of -10 mmHg).
Daily home use of FlowOx™ for 2 hours (divided into minimum two sessions of 1 hour) per day in PAD-patients with intermittent claudication (stage II acc.to EMA, equivalent to Fontaine stage IIb in Germany) relative to sham (placebo) will be provided over a period of 12 weeks.
This efficacy study is evaluating the clinical effects of INP on patient with intermittent claudication with special focus on changes in pain free walking distance and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmation of clinical diagnosis of PAD as objective evidence of Fontaine stage IIb PAD i.e.:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
Device: Active FlowOx™
The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
Device: Sham FlowOx™ (Placebo)
Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
Change in pain-free walking distance from baseline to week 12
The change will be calculated as difference in meters and compared between the interventional and the sham group.
Time frame: baseline to week 12
Change in maximal walking distance from baseline to week 12
The change will be calculated as difference in meters and compared between the interventional and the sham group.
Time frame: 3 months treatment
Change in Ankle Brachial index from baseline to week 12
Determination of the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium)
Time frame: from baseline to week 12
Change in Quality of Life from baseline to week 12: EQ-5D-5L
The 5-level EQ-5D (EuroQol- 5 Dimension) version (EQ-5D-5L) essentially consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). EQ-5D-5L describes the health condition of adults in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). Patient indicate their health states by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ-VAS score is read on a scale of 0-100 points (scale name: health condition), depending on where the patient has set his mark. 0 points mean the worst possible health condition, while 100 points is the best health possible.
Time frame: from baseline to week 12
Change in activity of daily living from baseline to week 12
To evaluate the activity of daily living the standardized questionnaire VascuQoL-6 is used which comprises a set of 6 questions. Each question is scored 1-4. The sum of each individual question score is used to generate a "Total" Score. A higher value indicates better health status.
Time frame: from baseline to week 12
Determination of compliance of subjects as assessed by the time the device has been running
The FlowOx device records the time the device has been running each time it was started. This record is saved on an USB stick which is readable by the study personnel only and serves to document the patient's compliance.
Time frame: at week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2019 to primary completion in Apr 2020, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peripheral Vascular Diseases →
Otivio AS